Consider the 2-3x Upside in this Most Overlooked Hepatitis B Stock
ByÂ Dr. Paul Nunzio De Santis and Jake King GlobeImmune (GBIM)Â IPOâ€™d in June to little fanfare and has underperformed the biotech...Read Now
Being Early on an Early Asset: Trillium May be A Diamon...
Trillium Therapeutics (TSX:TR) (OTC:SCTPF) is an immuno-oncology company developing novel cancer therapeutics. Trillium was founded in 2003 and went public...Read Now